Martínez Sellés Oliveria Soares, ManuelDatino Romaniega, TomásFigueiras-Graillet, LourdesGama, Joubert G.Jones, ChristopherFranklin, RichardFernández-Avilés, Francisco2013-11-272013-11-272013Martínez-Sellés, M., Datino, T., Figueiras-Graillet, L., Gama, J. G., Jones, C., Franklin, R., & Fernández-Avilés, F. (2013). Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions. Clinical Drug Investigation, 33(1), 45-54.http://hdl.handle.net/11268/1087Essential thrombocythaemia (ET) is a rare clonal myeloproliferative disorder characterized by a sustained elevation in platelet count and megakaryocyte hyperplasia. Anagrelide is used in the treatment of ET, where it has been shown to reduce platelet count. Anagrelide is metabolized by cytochrome P450 (CYP) 1A2, and previous studies of the effect of food on the bioavailability and pharmacokinetics of anagrelide were conducted prior to the identification of the active metabolite, 3-hydroxyanagrelide.engjournal article10.1007/s40261-012-0032-2restricted accessEnfermedad cardiovascularFarmacologíaDietética